Effects of prolonged infusions of the NMDA antagonist aptiganel hydrochloride (CNS 1102) in normal volunteers

Clinical Neuropharmacology

Volumn 20, Issue 4, 1997, Pages 311-321

  Muir, Keith W ^a,b   Grosset, Donald G ^a,b   Lees, Kennedy R ^a  

^a WESTERN INFIRMARY   (United Kingdom)

^b SOUTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Aptiganel hydrochloride; Blood pressure; CNS 1102; N methyl D aspartate; Noncompetitive antagonist

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; APTIGANEL; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID; RENIN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RESPONSE; CLINICAL TRIAL; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HALLUCINATION; HUMAN; HUMAN EXPERIMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MOTOR PERFORMANCE; MOTOR RETARDATION; NEUROPROTECTION; NORMAL HUMAN; PARESTHESIA; PLASMA RENIN ACTIVITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTION TIME; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VERTIGO;

EID: 0030877871     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002826-199708000-00003     Document Type: Article

References (15)

1. Rothman S. Synaptic release of excitatory amino acid neurotransmitter mediates anoxic neuronal death. J Neurosci 1984;4:1884-91.
2. Rothman SM, Olney JW. Glutamate and the pathophysiology of hypoxic-ischemic brain damage. Ann Neurol 1986;19:105-11.
3. Schanne FAX, Kane AB, Young EE, Farber FL. Calcium dependence of toxic cell death: a final common pathway. Science 1979;206:700-2.
4. Foster AC, Fagg GE. Taking apart NMDA receptors. Nature 1987;329:395-6.
5. McCulloch J. Excitatory amino acid antagonists and their potential for the treatment of ischemic brain damage in man. Br J Clin Pharmacol 1992;34:106-14.
6. Minematsu K, Fisher M, Li L, et al. Effects of a novel NMDA antagonist on experimental stroke rapidly and quantitatively assessed by diffusion-weighted MRI. Neurology 1993;43:397-403.
7. Meadows M-E, Fisher M, Minematsu K. Delayed treatment with a noncompetitive NMDA antagonist, aptiganel HCl, reduces infarct size in rats. Cerebrovasc Dis 1994;4:26-31.
8. Muir KW, Grosset DG, Gamzu E, Lees KR. Pharmacological effects of the noncompetitive NMDA antagonist aptiganel HCl in normal volunteers. Br J Clin Pharmacol 1994;38:33-8.
9. Hindmarch I. Psychomotor function and psychoactive drugs. Br J Clin Psychoactive drugs. Br J Clin Pharmacol 1980:10;189-209.
10. Howes LG, Miller SK, Reid JL. The simultaneous assay of 3,4 dihydroxyphenylethylene glycol and norepinephrine in human plasma by HPLC with electrochemical detection. J Chromatogr 1985;338:401-3.
11. Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects, of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 1994;51:199-214.
12. Fisher M. Cerestat (aptiganel HCl), a non-competitive NMDA antagonist, in ischemic stroke patients: dose-escalating safety study. Cerebrovasc Dis 1994;4:245.
13. Clark WM, Coull BM. Randomised trial of CGS19755, a glutamate antagonist, in acute ischemic stroke treatment [Abstract]. Neurology 1994;44(suppl 2):A270.
14. Albers GW, Atkinson R, Kelley R, Rosenbaum DM. Safety, tolerability, and pharmacokinetics of the N-methyl D-aspartate antagonist dextrorphan in patients with an acute stroke [Abstract]. Neurology 1994;44(suppl 2):A270-1.
15. Wahlgren NG, MacMahon DG, DeKeyser J, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischemic stroke. Cerebrovasc Dis 1994;4:204-10.